| Title |
Management of Pediatric Status Epilepticus
|
|---|---|
| Published in |
Current Treatment Options in Neurology, June 2014
|
| DOI | 10.1007/s11940-014-0301-x |
| Pubmed ID | |
| Authors |
Nicholas S. Abend, Tobias Loddenkemper |
| Abstract |
Status epilepticus (SE) is a medical emergency consisting of persistent or recurring seizures without a return to baseline mental status. SE can be divided into subtypes based on seizure types and underlying etiologies. Management should be implemented rapidly and based on pre-determined care pathways. The aim is to terminate seizures while simultaneously identifying and managing precipitant conditions. Seizure management involves "emergent" treatment with benzodiazepines (lorazepam intravenously, midazolam intramuscularly, or diazepam rectally) followed by "urgent" therapy (phenytoin/fosphenytoin, phenobarbital, levetiracetam or valproate sodium). If seizures persist, "refractory" treatments include infusions of midazolam or pentobarbital. Prognosis is dependent on the underlying etiology and seizure persistence. This article reviews the current management strategies for pediatric convulsive SE. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Czechia | 1 | <1% |
| Unknown | 130 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 18% |
| Other | 17 | 13% |
| Researcher | 14 | 11% |
| Student > Bachelor | 14 | 11% |
| Student > Postgraduate | 11 | 8% |
| Other | 19 | 15% |
| Unknown | 33 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 54 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Agricultural and Biological Sciences | 6 | 5% |
| Neuroscience | 6 | 5% |
| Nursing and Health Professions | 5 | 4% |
| Other | 12 | 9% |
| Unknown | 36 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2020.
All research outputs
#2,240,054
of 22,757,090 outputs
Outputs from Current Treatment Options in Neurology
#39
of 470 outputs
Outputs of similar age
#23,857
of 229,145 outputs
Outputs of similar age from Current Treatment Options in Neurology
#3
of 4 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 470 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,145 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.